dexamethasone | 124-94-7

• 物质功能分类: 原料药 - 激素及调节内分泌功能类药 - 肾上腺皮质激素类药
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: dexamethasone
• 英文别名: DMS；9α-Fluor-11β,16α,17α,21-tetrahydroxy-pregna-1,4-dien-3,20-dion；16α-Hydroxy-9α-flour-prednisolon；16α-Hydroxy-9α-fluor-prednisolon；Triamcinolon；Gfnanzimvaiwhm-mgvprkgpsa-；(9R,10S,11S,13S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• CAS: 124-94-7；7719-65-5；7719-67-7
• 化学式: C₂₁H₂₇FO₆
• 分子量: 394.44
• InChiKey: GFNANZIMVAIWHM-MGVPRKGPSA-N

物化性质

• 熔点：
  262-263 °C(lit.)
• 比旋光度：
  69 º (c=2, DMF)
• 沸点：
  587.5±50.0 °C(Predicted)
• 密度：
  1.1703 (estimate)
• 溶解度：
  在DMF中的溶解度为20mg/mL
• 稳定性/保质期：
  基本性质：肾上腺皮质激素及促肾上腺皮质激素类药物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S36
• 危险类别码：
  R40
• WGK Germany：
  3
• 海关编码：
  2937229000
• 危险品运输编号：
  OTH
• RTECS号：
  TU3850000
• 储存条件：
  贮存：室温下密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Triamcinolone
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H351: Suspected of causing cancer
P281: Use personal protective equipment as required

---

Section 3. Composition/information on ingredients.
Ingredient name: Triamcinolone
CAS number: 124-94-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C21H27FO6
Molecular weight: 394.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

醋酸曲安西龙（Triamcinolone）概述

醋酸曲安西龙（Triamcinolone）是一种肾上腺皮质激素及促肾上腺皮质激素药物，其抗炎作用比氢化可的松和泼尼松更强，但水钠潴留作用较轻微。口服易吸收，适用于类风湿性关节炎、其他结缔组织疾病、支气管哮喘、过敏性皮炎、神经性皮炎、湿疹等。特别适合对皮质激素禁忌且伴有高血压或水肿的关节炎患者。

适应症

利用其强大的免疫抑制作用，醋酸曲安西龙用于治疗各种变态反应性炎症和自身免疫性疾病。其主要药理作用与醋酸泼尼松（强的松）相似，因此适用证也基本相同，主要包括：

1. 系统性红斑狼疮等结缔组织病。
2. 肾病综合征等免疫性肾脏疾病。
3. 特发性血小板减少性紫癜等免疫性疾病。
4. 醋酸泼尼松适用的其他疾病。

生物活性

Triamcinolone是一种糖皮质激素，可采用游离醇或酯化形式口服、肌肉注射、局部注射、吸入或外用。用于治疗多种以皮质类固醇表示的疾病。

目标	值
肾上腺素受体	()

用途

作为激素类药物使用。

反应信息

• 作为反应物：
  描述：

  dexamethasone 、 2-(2-(methacryloyloxy)ethylsulfonyl)acetic acid 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 以60%的产率得到2-(2-(2-((8S,9R,10S,11S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[α]phenanthren-17-yl)-2-oxoethoxy)-2-oxoethylsulfinyl)ethyl methacrylate
  参考文献：
  名称：

  [EN] CONTROLLED RELEASE SYSTEM
  [FR] SYSTÈME DE LIBÉRATION CONTRÔLÉE

  摘要：

  本发明涉及除静脉注射外的可控释放系统。该可控释放系统针对活性成分，这些活性成分被包裹在或以其他方式纳入聚合物载体或聚合物设备中，例如胶束、纳米颗粒、微球和其他类型的聚合物设备，以进行可控释放；这些活性成分与聚合物载体或聚合物设备共价结合。该可控释放系统可适用于治疗疾病。

  公开号：

  WO2013002636A1

文献信息

• High-Molecular Weight Conjugate Of Steroids
  申请人：Kitagawa Masayuki

  公开号：US20100292414A1

  公开（公告）日：2010-11-18

  Enzymes in the body vary among different species, and also vary among individuals of the same species. Thus, it has been demanded to develop a novel steroid-containing pharmaceutical preparation which can release a drug in a manner independent of the enzymes present in the body, and which is expected to have an efficacious therapeutic effect. Disclosed is a high-molecular weight conjugate of a steroid, comprising a structure in which a carboxylic acid group of a polymer having a polyethylene glycol moiety and a succinic acid monoamide moiety having two or more succinic acid monoamide units is ester-bonded to a hydroxy group in the steroid.
• US8703878B2
  申请人：——

  公开号：US8703878B2

  公开（公告）日：2014-04-22
• USRE46190E1
  申请人：——

  公开号：USRE46190E1

  公开（公告）日：2016-11-01
• [EN] CONTROLLED RELEASE SYSTEM<br/>[FR] SYSTÈME DE LIBÉRATION CONTRÔLÉE
  申请人：CRISTAL DELIVERY B V

  公开号：WO2013002636A1

  公开（公告）日：2013-01-03

  The present invention relates to controlled release systems that may be administered other than intravenously. The controlled release system is directed to active ingredients, entrapped in or otherwise incorporated in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the active ingredients are covalently bonded to the polymer carriers or polymeric devices. The controlled release systems may suitably be used to treat diseases.

  本发明涉及除静脉注射外的可控释放系统。该可控释放系统针对活性成分，这些活性成分被包裹在或以其他方式纳入聚合物载体或聚合物设备中，例如胶束、纳米颗粒、微球和其他类型的聚合物设备，以进行可控释放；这些活性成分与聚合物载体或聚合物设备共价结合。该可控释放系统可适用于治疗疾病。

表征谱图